HAWK研究日本息肉状脉络膜血管病变亚组:布罗鲁珠单抗与阿柏西普96周疗效安全性比较
HAWK研究日本PCV亚组中,39眼接受布罗鲁珠单抗6mg(q12w/q8w),30眼接受阿柏西普2mg(固定q8w)。至96周,两组BCVA增益相当,布罗鲁珠单抗组视网膜积液消退更优,76%可维持q12w至48周,但眼内炎症发生率较高。
要点
- 布罗鲁珠单抗与阿柏西普在PCV眼中96周BCVA增益相当。
- 布罗鲁珠单抗组视网膜积液消退比例优于阿柏西普组。
- 布罗鲁珠单抗组76%可维持q12w至48周,眼内炎症率较高。
核心结论
- 在日本PCV眼中,布罗鲁珠单抗q12w/q8w单药治疗与阿柏西普q8w固定给药相比,BCVA增益相当且解剖学结局更优。
研究设计与样本
- HAWK为全球、2年、随机、双盲、多中心III期试验,纳入新生血管性年龄相关性黄斑变性参与者。
- 日本PCV亚组中39眼接受布罗鲁珠单抗6mg,30眼接受阿柏西普2mg。
主要发现
- BCVA从基线至48周/96周平均变化:布罗鲁珠单抗组+10.4/+11.4个ETDRS字母,阿柏西普组+11.6/+11.1个字母。
- 布罗鲁珠单抗组负荷期后仅q12w给药概率至48周为76%,至96周为68%。
- 48周时视网膜内液和/或视网膜下液比例:布罗鲁珠单抗组7.7%,阿柏西普组30%;96周时分别为12.8%和16.7%。
- 布罗鲁珠单抗总体耐受良好,但眼内炎症发生率高于阿柏西普。
关键数值与推荐
- 布罗鲁珠单抗6mg负荷期后每12周给药,发现疾病活动则调整为每8周;阿柏西普2mg固定每8周给药。
临床怎么用
- 对日本PCV患者,布罗鲁珠单抗q12w/q8w方案可在维持视力增益的同时延长给药间隔并更好消退积液。
- 使用布罗鲁珠单抗时需关注眼内炎症风险。
局限性
- 原文未报告亚组样本量以外的统计效能或P值等详细信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy (PCV) over 96 weeks in the HAWK study. DESIGN: HAWK was a global, 2-year, randomised, double-masked, multicentre phase III trial in participants with neovascular age-related macular degeneration. METHODS: Of the Japanese participants with PCV, 39 received brolucizumab 6 mg and 30 received aflibercept 2 mg. After 3 monthly loading doses, brolucizumab-treated eyes received an injection every 12 weeks (q12w) but were adjusted to q8w if disease activity was detected. Aflibercept-treated eyes received fixed q8w dosing. Mean change in best-corrected visual acuity (BCVA), the proportion of participants on q12w, retinal thickness, retinal fluid changes and safety were assessed to Week 96. RESULTS: Mean change in BCVA (early treatment diabetic retinopathy study (ETDRS) letters) from baseline to week 48/week 96 was+10.4/+11.4 for brolucizumab and +11.6/+11.1 for aflibercept. For brolucizumab-treated eyes, the probability of only q12w dosing after loading through week 48 was 76%, and 68% through week 96. Fluid resolution was greater with brolucizumab than aflibercept: respective proportions of eyes with intraretinal fluid and/or subretinal fluid were 7.7% and 30% at week 48% and 12.8% and 16.7% at week 96. Brolucizumab exhibited an overall well-tolerated safety profile despite a higher rate of intraocular inflammation compared with aflibercept. CONCLUSION: In Japanese eyes with PCV, brolucizumab q12w/q8w monotherapy resulted in robust and consistent BCVA gains that were comparable to q8w aflibercept dosing. Anatomical outcomes favoured brolucizumab over aflibercept, with 76% of brolucizumab participants maintained on q12w dosing after loading to week 48.
引用
- Ogura Y, Jaffe GJ, Cheung CMG, et al. Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK. Br J Ophthalmol. 2021. PMID: 34301613. doi:10.1136/bjophthalmol-2021-319090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。